You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

Details for Patent: 10,272,079

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,272,079 protect, and when does it expire?

Patent 10,272,079 protects XPHOZAH and is included in one NDA.

This patent has forty-eight patent family members in twenty-six countries.

Summary for Patent: 10,272,079

Title:	NHE3-binding compounds and methods for inhibiting phosphate transport
Abstract:	Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Inventor(s):	Carreras Christopher, Charmot Dominique, Jacobs Jeffrey W, Labonte Eric, Lewis Jason G.
Assignee:	ARDELYX, INC.
Application Number:	US14783983
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,272,079

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF HYPERPHOSPHATEMIA	⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				REDUCTION OF SERUM PHOSPHORUS IN ADULTS	⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				REDUCTION OF SERUM PHOSPHORUS IN ADULTS	⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF HYPERPHOSPHATEMIA	⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				REDUCTION OF SERUM PHOSPHORUS IN ADULTS	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,272,079

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095852	⤷ Try a Trial
Australia	2014250956	⤷ Try a Trial
Australia	2019204676	⤷ Try a Trial
Brazil	112015025805	⤷ Try a Trial
Canada	2909169	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.